Related Experiment Video
Updated: Dec 6, 2025

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid
Ankita Narayan1, Amanda Hunkele1, Jin Xu1
1Department of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.
Abstract:
The biased signaling has been extensively studied in the original mu opioid receptor (MOR-1), particularly through G protein and β-arrestin2 signaling pathways. The concept that the G protein pathway is often linked to the therapeutic effect of the drug, while the β-arrestin pathway is associated to the side effects has been proposed to develop biased analgesic compounds with limited side-effects associated with traditional opiates. The mu opioid receptor gene, OPRM1, undergoes extensive alternative pre-mRNA splicing, generating multiple splice variants or isoforms that are conserved from rodent to human. One type of the Oprm1 splice variants are the full-length 7 transmembrane (7TM) C-terminal splice variants, which have identical receptor structures including entire binding pocket, but contain a different intracellular C-terminal tail resulted from 3' alternative splicing. Increasing evidence suggest that these full-length 7TM C-terminal variants play important roles in mu opioid pharmacology, raising questions regarding biased signaling at these multiple C-terminal variants. In the present study, we investigated the effect of different C-terminal variants on mu agonist-induced G protein coupling, β-arrestin2 recruitment, and ultimately, signaling bias. We found that mu agonists produced marked differences in G protein activation and β-arrestin2 recruitment among various C-terminal variants, leading to biased signaling at various level. Particularly, MOR-1O, an exon 7-associated variant, showed greater β-arrestin2 bias for most mu agonists than MOR-1, an exon 4-associated variant. Biased signaling of G protein-coupled receptors has been defined by evidences that different agonists can produce divergent signaling transduction pathways through a single receptor. Our findings that a single mu agonist can induce differential signaling through multiple 7TM splice variants provide a new perspective on biased signaling at least for Oprm1, which perhaps is important for our understanding of the complex mu opioid actions in vivo where all the 7TM splice variants co-exist.
Insights
Mu opioid receptor (MOR) C-terminal variants exhibit distinct biased signaling profiles, influencing G protein and β-arrestin2 recruitment differently. This finding offers new insights into opioid pharmacology and the development of safer analgesics.
Area of Science:
- Pharmacology
- Molecular Biology
- Genetics
Background:
- Biased signaling in mu opioid receptor (MOR-1) involves G protein and β-arrestin2 pathways, with potential links to therapeutic effects and side effects.
- The mu opioid receptor gene (OPRM1) produces multiple full-length 7 transmembrane (7TM) splice variants with distinct C-terminal tails due to alternative splicing.
- These C-terminal variants are increasingly recognized for their roles in opioid pharmacology, necessitating an investigation into their specific signaling biases.
Purpose of the Study:
- To investigate how different C-terminal variants of MOR affect G protein coupling and β-arrestin2 recruitment upon mu agonist stimulation.
- To determine the extent of signaling bias induced by various C-terminal variants.
- To elucidate the impact of C-terminal variations on the differential signaling of MOR.
Main Methods:
- Characterization of G protein activation by mu agonists across different MOR C-terminal variants.
- Quantification of β-arrestin2 recruitment in response to mu agonists binding to various MOR variants.
- Comparative analysis of signaling bias among distinct MOR C-terminal isoforms.
Main Results:
- Mu agonists induced significant differences in G protein activation and β-arrestin2 recruitment among the studied C-terminal variants.
- The MOR-1O variant (exon 7-associated) displayed a greater β-arrestin2 bias compared to the MOR-1 variant (exon 4-associated) for most mu agonists.
- Evidence of biased signaling at multiple levels was observed across the different C-terminal variants.
Conclusions:
- A single mu agonist can elicit differential signaling through multiple 7TM splice variants of the mu opioid receptor.
- The C-terminal variants of MOR play a crucial role in determining the biased signaling profile.
- These findings provide a novel perspective on biased signaling for OPRM1 and may be vital for understanding complex in vivo opioid actions.
More Related Videos
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
09:09Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
Published on: September 20, 2016
Related Concept Videos
Opioid Receptors: Overview
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
RNA Splicing
GPCR Desensitization